What Axon Neurosciences does

Axon Neurosciences is a clinical-stage biotech company developing tau-based immunotherapeutics and diagnostics for Alzheimer's disease and related tauopathies. Founded in 1999 by Professor Michal Novák in Vienna, Austria, the company originated from his late-1980s discovery of tau protein as the structural component of neurofibrillary tangles at MRC Cambridge. Its core pipeline consists of AADvac1, an active vaccine that instructs the patient's immune system to produce antibodies selectively targeting pathological tau (the most clinically advanced tau therapy in development, having completed a positive Phase 2 ADAMANT trial published in Nature Aging), AADvac2, a humanized monoclonal antibody candidate against the same target, ACvac1, a pluri-epitope peptide vaccine designed for elderly and immunocompromised populations, and a complementary diagnostic program anchored by the proprietary p-tau T217 ultrasensitive immunoassay for discriminating AD from other dementias.

The company's technology is differentiated by a dual-mechanism approach that addresses both the formation and spread of pathological tau oligomers, and by selective targeting that preserves healthy tau — a critical safety feature. Axon claims the single biggest dedicated tau immunotherapy team in the world, supplemented by a Scientific Advisory Board including globally recognized AD researchers (Kaj Blennow, Bengt Winblad, Philip Scheltens, Khalid Iqbal, Howard Feldman). The company is pre-revenue and monetizes through future pharmaceutical commercialization (planned one-time license / product sales model), currently funded by USD 226 million in NIH grant commitments secured in February 2026 to support the ATP Phase 2 combination-therapy trial (450 participants) and a new PSP platform trial (440 participants) across the U.S. and Canada.

Operationally, Axon is headquartered in Vienna, Austria, with primary R&D operations in Bratislava, Slovakia at the Institute of Neuroimmunology (Slovak Academy of Sciences), and conducts clinical activities through a wholly-owned subsidiary structure (Axon Neuroscience CRM Services SE and Axon Neuroscience R&D Services SE). Leadership comprises CEO Michal Fresser (appointed 2019, previously general counsel since 2013), CSO Norbert Žilka (with Axon since 1999), CFO Ladislav Satko (since 2011), and COO Branislav Kováčech (since 2002, who led AADvac1 advancement). No external private equity or venture capital ownership has been disclosed; the company remains founder-driven with co-founder Prof. Novák on the board.

Name

Axon Neurosciences

Legal name

Axon Neuroscience

Website

https://axon-neuroscience.eu

Company type

Private

Founded year

1999

Operating status

Operating

Headcount range

101–250 employees

Short description

Axon Neurosciences is a clinical-stage biotech founded in 1999 developing tau-targeting immunotherapies (AADvac1 vaccine, AADvac2 monoclonal antibody) and p-tau diagnostics for Alzheimer's disease and related tauopathies, currently funded by USD 226 million in NIH grants for U.S. Phase 2 trials.

Ownership category

akta.pro rank

Product category

Alzheimer's Disease Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

akta.pro secondary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

Keywords

• Tau immunotherapy
• Alzheimer's therapeutics
• Neurodegenerative disease research
• Tau vaccines
• Clinical-stage biotech

Headquarters

HQ city

Larnaca

HQ country

Cyprus

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Others

Revenue model

1. Pharmaceutical Development and Commercialization: As a clinical-stage biotech company, Axon Neuroscience is focused on developing tau-based treatments for Alzheimer's disease. The company does not yet have commercialized products and is in the revenue generation phase through clinical trials. Future revenue will come from pharmaceutical product sales upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Axon Neurosciences is a clinical-stage biotech company developing tau-based therapeutics and diagnostics for Alzheimer's disease and related tauopathies. Its portfolio includes active tau immunotherapy vaccines (AADvac1, ACvac1), a humanized monoclonal antibody (AADvac2), and a diagnostic immunoassay (p-tau T217) that targets pathological tau proteins while preserving healthy tau. The company's products are aimed at halting disease progression, relieving symptoms, and preventing onset in at-risk individuals.

Product overview

Axon Neuroscience is a clinical-stage biotech company developing tau-based therapeutics and diagnostics for Alzheimer's disease and related tauopathies. The product portfolio consists of three therapeutic candidates (AADvac1, AADvac2, ACvac1) and a diagnostic program. AADvac1 is an active tau immunotherapy vaccine (most clinically advanced tau therapy), AADvac2 is a humanized monoclonal antibody, and ACvac1 is a pluri-epitope peptide vaccine. The diagnostic program includes the p-tau T217 ultrasensitive immunoassay for detecting AD biomarkers in cerebrospinal fluid and blood, along with a broader research program using miRNA, metabolomics, peptidomics, and proteomics.

Differentiator

Problem solved

Functional benefit

Brands

• AADvac1: Active tau immunotherapy vaccine candidate for Alzheimer's disease - the most clinically-advanced tau therapy in development for Alzheimer's disease.
• AADvac2
• ACvac1
• p-tau T217 ultrasensitive immunoassay

Products and services

• AADvac1 Active tau immunotherapy vaccine candidate for Alzheimer's disease; the most clinically-advanced tau therapy in development. It instructs the patient's immune system to produce specific antibodies targeting pathological tau proteins while preserving healthy tau, with potential to address pre-symptomatic disease stages 10-20 years prior to symptom onset.
• AADvac2 Humanized monoclonal antibody candidate for Alzheimer's disease produced in laboratory conditions and delivered to patients to target pathological tau proteins, complementing Axon's active vaccine approach.
• ACvac1 Pluri-epitope peptide vaccine approach with selectivity, specificity, and safety advantages over conventional vaccines. Designed to stimulate robust immune response in elderly populations and people with immunodeficiencies.
• p-tau T217 Ultrasensitive Immunoassay Leading diagnostic immunoassay based on detection of phosphorylated T217 tau species in cerebrospinal fluid and blood. Can specifically discriminate Alzheimer's disease patients from patients with other dementias and tau-related disorders.
• Diagnostic Assay Program Research program on novel Alzheimer's disease biomarkers in cerebrospinal fluid and blood using miRNA, metabolomics, peptidomics, and proteomics technologies for diagnostic and prognostic capabilities.

Quantifiable outcome

• Phase 2 ADAMANT trial demonstrated excellent safety profile and supportive clinical effects in 24-month study
• +2 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Alzheimer's Tau Platform (ATP)coreStrategic or Co-development PartnerAADvac1 selected as the first tau-targeted therapy to enter the ATP phase 2 combination-therapy trial, evaluating the therapy both as monotherapy and in combination with an approved anti-amyloid antibody in approximately 450 participants with late preclinical or early prodromal Alzheimer's disease.
• Progressive Supranuclear Palsy (PSP) Platform TrialcoreStrategic or Co-development PartnerAADvac1 selected for new U.S. platform trial for PSP conducted across 50 clinical centers in the U.S. and Canada, enrolling approximately 440 patients. The therapy will be evaluated alongside AZP2006 from AlzProtect.
• AlzProtectminorStrategic or Co-development PartnerAZP2006 from AlzProtect will be evaluated alongside AADvac1 in the PSP platform trial, representing a co-development partnership for combination therapy evaluation.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Prothena Corporation: Clinical-stage biotech developing anti-tau and anti-amyloid monoclonal antibodies for Alzheimer's disease and other neurodegenerative disorders. Direct peer in tau-targeting antibody development.
• AC Immune SA: Clinical-stage biopharmaceutical company developing both active vaccines (ACI-35) and passive antibodies against pathological tau and alpha-synuclein for Alzheimer's and Parkinson's. Most direct competitor to Axon in the tau immunotherapy space.
• TauRx Therapeutics: Clinical-stage company developing tau aggregation inhibitors (e.g., hydromethylthionine mesylate) for Alzheimer's and frontotemporal dementia. Closely comparable therapeutic modality (tau-targeting) and clinical-stage profile.
• AlzProtect: French clinical-stage biotech developing therapeutics for tauopathies including progressive supranuclear palsy. Direct co-development peer in the NIH-funded PSP platform trial alongside AADvac1.

Broad incumbents

• Biogen: Major biopharmaceutical company with established Alzheimer's franchise (Leqembi/aducomab/lecanemab) and active tau-targeting research programs. Comparable as incumbent AD player; partner in the ATP combination trial that Axon is entering.
• Eisai: Established AD drug developer (Leqembi co-developer with Biogen) and operator of major Alzheimer's clinical infrastructure. Relevant as incumbent shaping the standard-of-care landscape against which Axon's tau therapy will be positioned.
• Roche / Genentech: Major incumbent with a large Alzheimer's pipeline spanning anti-amyloid antibodies, tau-targeting programs, and CNS diagnostics. Represents the broader strategic-pharma competitive context for tau immunotherapy.
• Eli Lilly: Major pharma with FDA-approved AD therapy (Kisunla/donanemab) and broad neuroscience pipeline. Sets competitive pricing and clinical benchmark for any new disease-modifying AD entrant.

Emerging players

• Cassava Sciences: Clinical-stage biotech developing simufilam for Alzheimer's disease. Comparable as a late-stage small-cap AD biotech, though with a different (non-tau) mechanism.
• C2N Diagnostics: Developer of blood-based biomarkers (PrecivityAD) for Alzheimer's disease, including p-tau217 assays. Direct comparable in the AD blood-based diagnostic space where Axon's p-tau T217 assay also competes.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/3583617
• Xx.com/alzassociation
• Facebookfacebook.com/actionalz

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Subsidiaries2 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Axon Neurosciences